EA200601803A1 - Пиридилзамещенные порфириновые соединения и способы их применения - Google Patents

Пиридилзамещенные порфириновые соединения и способы их применения

Info

Publication number
EA200601803A1
EA200601803A1 EA200601803A EA200601803A EA200601803A1 EA 200601803 A1 EA200601803 A1 EA 200601803A1 EA 200601803 A EA200601803 A EA 200601803A EA 200601803 A EA200601803 A EA 200601803A EA 200601803 A1 EA200601803 A1 EA 200601803A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pyridyl
methods
substituted porphyrin
resulting
disease
Prior art date
Application number
EA200601803A
Other languages
English (en)
Other versions
EA010834B1 (ru
Inventor
Уилльям Уилльямс
Гарри Саутан
Чаба Сабо
Original Assignee
Инотек Фармасьютикалз Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Инотек Фармасьютикалз Корпорейшн filed Critical Инотек Фармасьютикалз Корпорейшн
Publication of EA200601803A1 publication Critical patent/EA200601803A1/ru
Publication of EA010834B1 publication Critical patent/EA010834B1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/16Emollients or protectives, e.g. against radiation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F11/00Compounds containing elements of Groups 6 or 16 of the Periodic Table
    • C07F11/005Compounds containing elements of Groups 6 or 16 of the Periodic Table compounds without a metal-carbon linkage
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00Compounds containing elements of Groups 7 or 17 of the Periodic Table
    • C07F13/005Compounds without a metal-carbon linkage
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/02Iron compounds
    • C07F15/025Iron compounds without a metal-carbon linkage

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Obesity (AREA)

Abstract

Настоящее изобретение относится к пиридилзамещенным порфириновым соединениям, композициям, содержащим эффективное количество пиридилзамещенного порфиринового соединения, и к способам лечения или профилактики повреждения, возникающего в результате действия химически активных видов, эректильной дисфункции, являющейся результатом операции, заболевания легких, гипероксии, нейродегенеративного заболевания, заболевания печени, поражения миокарда во время кардиоплегии, воспалительного состояния, повреждения, связанного с реперфузией, ишемического состояния, сердечно-сосудистого заболевания, диабета, диабетического осложнения, опухолей, побочного эффекта, возникающего в результате химиотерапии опухолей, или поражения, вызываемого облучением, и к продлению времени полужизни соединения, подверженного окислению, способам, включающим в себя введение субъекту при необходимости эффективного количества пиридилзамещенного порфиринового соединения.
EA200601803A 2004-03-29 2005-03-25 Пиридилзамещённые порфириновые соединения и способы их применения EA010834B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55755104P 2004-03-29 2004-03-29
US62846504P 2004-11-16 2004-11-16
PCT/US2005/010167 WO2005097123A2 (en) 2004-03-29 2005-03-25 Pyridyl-substituted porphyrin compounds and methods of use thereof

Publications (2)

Publication Number Publication Date
EA200601803A1 true EA200601803A1 (ru) 2007-10-26
EA010834B1 EA010834B1 (ru) 2008-12-30

Family

ID=35125604

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200601803A EA010834B1 (ru) 2004-03-29 2005-03-25 Пиридилзамещённые порфириновые соединения и способы их применения

Country Status (11)

Country Link
US (2) US7432369B2 (ru)
EP (1) EP1740094A4 (ru)
JP (1) JP2007530695A (ru)
KR (1) KR20060135922A (ru)
AU (1) AU2005231336A1 (ru)
BR (1) BRPI0509359A (ru)
CA (1) CA2561266A1 (ru)
EA (1) EA010834B1 (ru)
IL (1) IL178331A0 (ru)
MX (1) MXPA06011244A (ru)
WO (1) WO2005097123A2 (ru)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2397067B (en) * 2002-12-23 2005-05-11 Destiny Pharma Ltd Porphin & azaporphin derivatives with at least one cationic-nitrogen-containing meso-substituent for use in photodynamic therapy & in vitro sterilisation
AU2005231336A1 (en) * 2004-03-29 2005-10-20 Inotek Pharmaceuticals Corporation Pyridyl-Substituted Porphyrin Compounds and methods of use thereof
GB2415372A (en) 2004-06-23 2005-12-28 Destiny Pharma Ltd Non photodynamical or sonodynamical antimicrobial use of porphyrins and azaporphyrins containing at least one cationic-nitrogen-containing substituent
CA2622988A1 (en) * 2005-09-28 2007-04-05 Inotek Pharmaceuticals Corporation N-benzyl substituted pyridyl porphyrin compounds and methods of use thereof
KR20080065704A (ko) * 2005-11-09 2008-07-14 콤비네이토릭스, 인코포레이티드 의학적 이상의 치료 방법들, 조성물들, 및 키트들
US20100120738A1 (en) * 2006-09-11 2010-05-13 Bernard Malfroy-Camine Anti-apoptotic benzodiazepine receptor ligand inhibitors
SI2056675T1 (sl) 2006-10-12 2019-08-30 Galera Labs, Llc Postopki za zdravljenje oralnega mukozitisa
KR20080047959A (ko) * 2006-11-27 2008-05-30 주식회사 엠디바이오알파 비만, 당뇨, 대사성 질환, 퇴행성 질환 및 미토콘드리아이상 질환의 치료 또는 예방을 위한 나프토퀴논계 약제조성물
EP2192899B1 (en) * 2007-08-28 2014-10-01 Technion Research and Development Foundation, Ltd. Transition metal complexes of corroles for preventing cardiovascular diseases or disorders
KR101405823B1 (ko) * 2007-12-24 2014-06-12 주식회사 케이티앤지생명과학 녹내장의 치료 및 예방을 위한 약제 조성물
KR20090071829A (ko) * 2007-12-28 2009-07-02 주식회사 머젠스 신장질환의 치료 및 예방을 위한 약제 조성물
US20090257999A1 (en) * 2007-12-31 2009-10-15 Inotek Pharmaceuticals Corporation Method of preventing contrast-induced nephropathy
JP5669123B2 (ja) * 2009-03-17 2015-02-12 国立大学法人 東京大学 発光によるビタミンc検出法及び定量法
JP4510929B1 (ja) * 2009-04-09 2010-07-28 パナソニック株式会社 テロメラーゼ反応阻害方法およびそれに用いられるテロメラーゼ反応阻害剤
CN102006871B (zh) * 2009-04-09 2013-05-22 松下电器产业株式会社 端粒酶反应的抑制方法
US20120135973A1 (en) * 2010-09-08 2012-05-31 Southern Illinois University Edwardsville Method for treating chronic pain
CN103906756B (zh) 2011-09-26 2020-03-03 加莱拉实验室有限责任公司 用于治疗疾病的方法
US9572816B2 (en) 2012-10-25 2017-02-21 Technion Research And Development Foundation Ltd. Method of treatment of disease
WO2015040622A1 (en) * 2013-09-22 2015-03-26 Laster Brenda The continuous long-term controlled release of telomerase inhibitors
US9034596B1 (en) 2014-04-17 2015-05-19 Kuwait University Method for fluorescent staining of cellular and intracellular membranes
WO2019152661A1 (en) * 2018-01-31 2019-08-08 Galera Labs, Llc Combination cancer therapy with pentaaza macrocyclic ring complex and platinum-based anticancer agent

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4822899A (en) 1985-04-12 1989-04-18 The University Of Michigan Metallic porphyrin complexes as catalysts in epoxidation reactions
US5990363A (en) 1987-01-02 1999-11-23 Sun Company, Inc. Method for oxidizing alkanes using novel porphyrins synthesized from dipyrromethanes and aldehydes
US5227405A (en) 1987-03-31 1993-07-13 Duke University Superoxide dismutase mimic
US5223538A (en) 1987-03-31 1993-06-29 Duke University Superoxide dismutase mimic
JPH0338587A (ja) 1989-07-03 1991-02-19 Doujin Kagaku Kenkyusho:Kk 酸化反応を触媒する標識化合物
US6204259B1 (en) 1993-01-14 2001-03-20 Monsanto Company Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
US5994339A (en) 1993-10-15 1999-11-30 University Of Alabama At Birmingham Research Foundation Oxidant scavengers
US6127356A (en) 1993-10-15 2000-10-03 Duke University Oxidant scavengers
US5747026A (en) 1993-10-15 1998-05-05 University Of Alabama At Birmingham Research Foundation Antioxidants
FR2717385B1 (fr) 1994-03-21 1996-04-19 Oreal Composition cosmétique contenant en association une superoxyde dismutase et une porphyrine.
US6245758B1 (en) 1994-05-13 2001-06-12 Michael K. Stern Methods of use for peroxynitrite decomposition catalysts, pharmaceutical compositions therefor
WO1996009053A1 (en) 1994-09-20 1996-03-28 Duke University Oxidoreductase activity of manganic porphyrins
US6013241A (en) 1995-01-23 2000-01-11 Schering Aktiengesellschaft Use of porphyrin-complex or expanded porphyrin-complex compounds as an infarction localization diagnosticum
AU6031096A (en) 1995-06-05 1996-12-24 Duke University Nitrosylated and nitrated superoxide oxidants and reductants
JPH11509180A (ja) * 1995-06-07 1999-08-17 デューク・ユニバーシティ 酸化体脱除剤
US6002026A (en) 1996-07-26 1999-12-14 The Trustees Of Princeton University Catalytic oxygenation of hydrocarbons by metalloporphyrin and metallosalen complexes
DE19647640A1 (de) 1996-11-18 1998-05-20 Basf Ag Monoverbrückte Porphyrin-Dimere und deren Metallkomplexe, Verfahren zu deren Herstellung sowie katalytische Verfahren unter Verwendung der Metallporphyrinkomplexe
EP0988037A1 (en) 1997-02-05 2000-03-29 Board Of Regents, The University Of Texas System Porphyrin compounds as telomerase inhibitors
IL135949A0 (en) * 1997-11-03 2001-05-20 Univ Duke Substituted porphyrins
US6194566B1 (en) 1997-12-02 2001-02-27 Schering Aktiengesellschaft Process for the production of metalloporphyrin-metal complex conjugates
US6479477B1 (en) 1998-04-24 2002-11-12 Duke University Substituted porphyrins
IL126953A0 (en) 1998-11-08 1999-09-22 Yeda Res & Dev Pharmaceutical compositions comprising porphyrins and some novel porphyrin derivatives
BR0007720B1 (pt) 1999-01-25 2014-04-08 Univ Duke Porfirinas substituídas e método de proteção de células contra toxicidade induzida por oxidante
US6448239B1 (en) * 1999-06-03 2002-09-10 Trustees Of Princeton University Peroxynitrite decomposition catalysts and methods of use thereof
AU1087401A (en) 1999-10-13 2001-04-23 Uab Research Foundation Metalloporphyrin treatment of neurologic disease
US20030069281A1 (en) 2000-06-14 2003-04-10 Irwin Fridovich Tetrapyrroles
US6403788B1 (en) 2000-07-11 2002-06-11 Eukarion, Inc. Non-genotoxic metalloporphyrins as synthetic catalytic scavengers of reactive oxygen species
US6573258B2 (en) 2000-09-27 2003-06-03 Frontier Scientific, Inc. Photodynamic porphyrin antimicrobial agents
AU2002312194B8 (en) * 2001-06-01 2008-05-15 Aeolus Sciences, Inc. Oxidant scavengers for treatment of diabetes or use in transplantation or induction of immune tolerance
GB0114155D0 (en) 2001-06-11 2001-08-01 Unilever Plc Complex for catalytically bleaching a substrate
US20030086916A1 (en) * 2001-10-12 2003-05-08 Goligorsky Michael S. Use of peroxynitrite scavengers or peroxynitrite formation inhibitors that do not diminish nitric oxide synthesis or activity to reverse or prevent premature vascular senescence
FR2837202B1 (fr) 2002-03-15 2007-08-31 Centre Nat Rech Scient Nouveaux derives de porphyrines, leur procede de preparation compositions pharmaceutiques et utilisations
CN100420689C (zh) * 2002-04-08 2008-09-24 巩宪昌 带有大取代基的卟啉衍生物、其制备方法及其作为小分子抗氧化剂的应用
US6650137B2 (en) * 2002-04-11 2003-11-18 Daimlerchrysler Corporation Circuit for monitoring an open collector output circuit with a significant offset
CA2488500A1 (en) 2002-06-07 2003-12-18 Duke University Substituted porphyrins
EP1718201B1 (en) * 2004-02-09 2016-09-14 Duke University Substituted porphyrins
AU2005231336A1 (en) * 2004-03-29 2005-10-20 Inotek Pharmaceuticals Corporation Pyridyl-Substituted Porphyrin Compounds and methods of use thereof
CA2622988A1 (en) 2005-09-28 2007-04-05 Inotek Pharmaceuticals Corporation N-benzyl substituted pyridyl porphyrin compounds and methods of use thereof
EP1962597A4 (en) 2005-11-30 2008-12-17 Inotek Pharmaceuticals Corp PURINE DERIVATIVES AND METHOD OF USE

Also Published As

Publication number Publication date
EP1740094A4 (en) 2008-09-03
US20060003982A1 (en) 2006-01-05
US7432369B2 (en) 2008-10-07
WO2005097123A3 (en) 2005-12-22
EP1740094A2 (en) 2007-01-10
IL178331A0 (en) 2007-02-11
EA010834B1 (ru) 2008-12-30
CA2561266A1 (en) 2005-10-20
KR20060135922A (ko) 2006-12-29
WO2005097123A2 (en) 2005-10-20
US20080009473A1 (en) 2008-01-10
MXPA06011244A (es) 2007-04-13
BRPI0509359A (pt) 2007-09-04
AU2005231336A1 (en) 2005-10-20
JP2007530695A (ja) 2007-11-01

Similar Documents

Publication Publication Date Title
EA200601803A1 (ru) Пиридилзамещенные порфириновые соединения и способы их применения
WO2007038630A3 (en) N-benzyl substituted pyridyl porphyrin compounds and methods of use thereof
BRPI0607240A2 (pt) derivados de maleimida, composições farmacêuticas e métodos para tratamento de cáncer
SMT201300096B (it) Inibitori di prolil idrossilasi
EA200601558A1 (ru) Производные изохинолинов и способы их использования
NO20074737L (no) Isokinolinforbindelser og fremgangsmater for anvendelse derav
EA200600689A1 (ru) Замещённые бензазолы и их применение в качестве ингибиторов raf киназы
WO2007125405A3 (en) Substituted 2-amino-fused heterocyclic compounds
EA201170061A1 (ru) Новые производные фенилимидазола в качестве ингибиторов фермента pde10a
EA201200021A1 (ru) Фунгицидные смеси
WO2006120573A3 (en) Heterocyclic n-oxides as hypoxic selective protein kinase inhibitors
AR036597A1 (es) Derivados de 1h-imidazol que tienen actividad agonista de cb1, agonista parcial de cb1 o antagonista de cb1
EA200901212A1 (ru) 3-имидазолилиндолы, предназначенные для лечения пролиферативных заболеваний
TW200730532A (en) Camptothecin derivatives as chemoradiosensitizing agents
DK1885187T3 (da) Fremgangsmåde til behandling af lægemiddelresistent cancer
EA201001094A1 (ru) Производные индазола
EA201001196A1 (ru) Соединения 4-пиридинона и их применение для лечения рака
ATE526025T1 (de) Behandlung metastasierter tumore
EA202090959A1 (ru) Аминзамещенные гетероциклические соединения в качестве ингибиторов ehmt2, их соли и способы их синтеза
Saada et al. Mono-and di-halogenated histamine, histidine and carnosine derivatives are potent carbonic anhydrase I, II, VII, XII and XIV activators
EA202191144A1 (ru) Состав ингибитора bcl-2 на основе циклодекстрина
EA200800788A1 (ru) Фунгицидные смеси на основе триазолов
ATE538105T1 (de) Substituierte tetrazolverbindungen und ihre verwendung
UA90340C2 (ru) Фунгицидная смесь на основе триазолов, композиция на ее основе и способ борьбы с фитопатогенными грибами
EA200800776A1 (ru) Производные хинолина и применение в качестве противоопухолевых агентов

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU